336 related articles for article (PubMed ID: 16959792)
1. Immunogenicity of biopharmaceuticals.
Kessler M; Goldsmith D; Schellekens H
Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v9-12. PubMed ID: 16959792
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence and the immunogenicity of biopharmaceuticals.
Schellekens H
Nat Rev Drug Discov; 2002 Jun; 1(6):457-62. PubMed ID: 12119747
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
4. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.
Tamilvanan S; Raja NL; Sa B; Basu SK
J Drug Target; 2010 Aug; 18(7):489-98. PubMed ID: 20192653
[TBL] [Abstract][Full Text] [Related]
5. Industry views of biosimilar development in Japan.
Horikawa H; Tsubouchi M; Kawakami K
Health Policy; 2009 Jul; 91(2):189-94. PubMed ID: 19157628
[TBL] [Abstract][Full Text] [Related]
6. Comparative testing and pharmacovigilance of biosimilars.
Locatelli F; Roger S
Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: pharmacovigilance and risk management.
Zuñiga L; Calvo B
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
[TBL] [Abstract][Full Text] [Related]
8. Follow-on biologics: challenges of the "next generation".
Schellekens H
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals.
Blackstone EA; Fuhr JP
Future Med Chem; 2010 Nov; 2(11):1641-9. PubMed ID: 21428836
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of biopharmaceuticals. The European perspective.
Schellekens H; Casadevall N
Dev Biol (Basel); 2003; 112():23-8. PubMed ID: 12762501
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Immunogenicity of Biopharmaceuticals.
Pineda C; Castañeda Hernández G; Jacobs IA; Alvarez DF; Carini C
BioDrugs; 2016 Jun; 30(3):195-206. PubMed ID: 27097915
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of therapeutic proteins. Part 1: impact of product handling.
Sharma B
Biotechnol Adv; 2007; 25(3):310-7. PubMed ID: 17336479
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
Jelkmann W
Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the immunogenicity of therapeutic proteins.
Schellekens H
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi3-9. PubMed ID: 15958824
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
[TBL] [Abstract][Full Text] [Related]
17. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.
Patten PA; Schellekens H
Dev Biol (Basel); 2003; 112():81-97. PubMed ID: 12762507
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of therapeutic proteins. Part 2: impact of container closures.
Sharma B
Biotechnol Adv; 2007; 25(3):318-24. PubMed ID: 17337336
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters.
Barbosa MD
Drug Discov Today; 2011 Apr; 16(7-8):345-53. PubMed ID: 21300174
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars--science, status, and strategic perspective.
Kresse GB
Eur J Pharm Biopharm; 2009 Aug; 72(3):479-86. PubMed ID: 19286455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
